key: cord-0958507-45r6rgon
authors: Masotti, Luca; Grifoni, Elisa; Pelagalli, Giulia; Cioni, Elisa; Mattaliano, Chiara; Cioffi, Elisa; Maggi, Francesca; Pinto, Gabriele; Maria Madonia, Elisa; Micheletti, Irene; Maria Grazia Gelli, Anna; Ciambotti, Benedetta; Mannucci, Amanda; Bello, Roberta; Cei, Francesco; Dolenti, Silvia; Tarquini, Roberto; Montenora, Iolanda; Spina, Rosario; Vanni, Simone
title: Prognostic role of Interleukin-6/lymphocytes ratio in SARS-CoV2 related pneumonia
date: 2021-12-10
journal: Int Immunopharmacol
DOI: 10.1016/j.intimp.2021.108435
sha: 22603b9a26d446f402dc5c7252cc8b1f00f78fc2
doc_id: 958507
cord_uid: 45r6rgon

INTRODUCTION AND AIM: Interleukin-6 to lymphocyte (IL-6/Lym) ratio has been identified as a potential prognostic tool in patients with SARS-CoV2 related pneumonia. The aim of our study was to compare the prognostic power of IL-6/Lym ratio with other biomarkers in patients initially admitted in a non intensive unit and suffering for respiratory failure associated with SARS-CoV2 related pneumonia. MATERIALS AND METHODS: IL-6/Lym ratio, IL-6, D-Dimer, D-Dimer/fibrinogen ratio, fibrinogen, C-reactive protein (CRP), lymphocytes count and neutrophil/lymphocyte (N/L) ratio collected at hospital admission were tested as prognosticators of negative outcome, defined as combined endpoint in-hospital mortality and/or Intensive Care Unit (ICU) admission requiring oro-tracheal intubation (OTI). RESULTS: Study population encompassed two hundreds and twenty-three patients (46% females) with mean age ± DS 69.4 ± 13.3 years. Eighty-nine patients (39.9%) suffered for severe respiratory failure and required non invasive ventilation, helmets and/or high flow nasal cannula. Fourty-one patients (18.3%) died during hospital stay and/or required OTI. In these patients mean values of IL-6/Lym ratio, IL-6, CRP and N/L were significantly higher and lymphocytes count was significantly lower compared with patients discharged alive and/or not requiring OTI, while no difference was found in mean values of D-Dimer, D-Dimer/Fibrinogen ratio and fibrinogen. AUC (0.797, 95% CI: 0.738-0.848) of IL-6/Lym ratio was the highest compared with those of all the other analyzed biomarkers and the difference was significant with the exception of IL-6. At multivariate logistic regression IL-6/Lym ratio > 66.5 resulted the only independent biomarker associated with mortality and/or OTI (OR 5.65; 95% 1.63-19.54). Conclusion: IL-6/Lym ratio seems to be an optimal prognosticator in SARS-CoV2 related pneumonia. Its routinary use in COVID-19 patients could be warranted.

ABSTRACT Introduction and aim: Interleukin-6 to lymphocyte (IL-6/Lym) ratio has been identified as a potential prognostic tool in patients with SARS-CoV2 related pneumonia. The aim of our study was to compare the prognostic power of IL-6/Lym ratio with other biomarkers in patients initially admitted in a non intensive unit and suffering for respiratory failure associated with SARS-CoV2 related pneumonia. Materials and methods: IL-6/Lym ratio, IL-6, D-Dimer, D-Dimer/fibrinogen ratio, fibrinogen, C-reactive protein (CRP), lymphocytes count and neutrophil/lymphocyte (N/L) ratio collected at hospital admission were tested as prognosticators of negative outcome, defined as combined endpoint in-hospital mortality and/or Intensive Care Unit (ICU) admission requiring oro-tracheal intubation (OTI) Moreover, the Authors found a cut off of 2.50 in IL-6/Lym ratio as discriminant for defining low (< 2.50) and high (≥ 2.50) risk patients. Interestingly, in the paper of Yang B. et al the IL-6/Lym ratio seems to be the best prognosticator of poor prognosis between demographic and co-morbidity data, and a lot of blood routine, biochemical, coagulation and immune-inflammatory indices (3) . To date, no external validation and/or other literature evidence about the predictive power of IL-6/Lym ratio in COVID-19 patients has been reported, therefore the aim of this study was to report our experience about the prognostic role of IL-6/Lym ratio in patients initially admitted in a non intensive unit and suffering for respiratory failure associated with SARS-CoV2 related pneumonia.

We retrospectively analyzed clinical and laboratory data of consecutive patients admitted in a non intensive unit for respiratory failure associated with SARS-CoV2 related pneumonia during the first and second wave of pandemic in Italy (first wave March-April 2020, second wave October-November 2020). We tested the predictive role of IL-6/Lym ratio as risk factor for negative outcome compared with IL-6, D-Dimer, 

Assessing the prognosis of patients with respiratory failure associated with SARS-CoV2 related pneumonia is fundamental in clinical practice. Cytokine storm represents the cornerstone of SARs-CoV2 related pneumonia and maybe it's the major determinant of poor prognosis and a potential target of pharmacological treatment (4). IL-6 plays a pivotal role on inflammation with a pleiotropic effect on liver, B cells, T cells, monocytes and platelets. In response to acute infection, IL-6 stimulates acute phase reactants, immune response and hematopoiesis (5) . Despite the exact pathophysiology mechanism remains unclear, much literature evidence shows that high levels of IL-6 and low lymphocytes count are biomarkers of cytokine storm and immune response in COVID-19 patients and their prognosis (6) . However the predictive power of these biomarkers is evaluated singularly. Combining two biomarkers by using the ratio between them could increase their predictive power. In COVID-19 patients lymphocytes count has been included in a lot of ratios with other biomarkers for testing outcomes such as Neu/Lym ratio (7), platelets/Lym ratio (8), Lym/CRP ratio (9), lymphocyte to monocyte ratio (10), eosinophil to lymphocyte ratio (11) . As abovementioned, recently IL-6/Lym ratio has been proposed as an interesting prognosticator in patients with COVID-19. In the present study, we confirm the findings of Yang B. et al (3) showing that IL-6/Lym has high power to predict negative outcome in patients with respiratory failure associated with SARS-CoV2 infection. Of note, we found that compared with other biomarkers, IL-6/Lym has the best predictive power and that between the analyzed biomarkers it's the only independent risk factor for mortality and/or OTI increasing the risk of more than five-fold.

We recognize that our study has limitations, main of these due to retrospective design, relative small sample size and single center. However our study could add information about the knowledge of prognosis of COVID-19 patients and important relapse for clinical practice.

In conclusion, in our study IL-6/Lym ratio seems to predict better than IL-6 and lymphocytes count alone and other inflammatory and coagulative biomarkers. Its routinary use as prognosticator in COVID-19 patients could be warranted. 

Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate

Biomarkers of cytokine storm as red flags for severe and fatal COVID-19 cases: A living systematic review and meta-analysis. PLoS One

The role of IL-6/lymphocyte ratio in the peripheral blood of severe patients with COVID-19

Controlling Cytokine Storm Is Vital in COVID-19

The Role of Interleukin 6 During Viral Infections

Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications

Prognostic value of neutrophil-to-lymphocyte ratio in COVID-19 patients: A systematic review and meta-analysis

Motoc NS et al Neutrophil-to-lymphocyte ratio, platelets-tolymphocyte ratio, and eosinophils correlation with high-resolution computer tomography severity score in COVID-19 patients

Lymphocyte-to-C-Reactive Protein Ratio: A Novel Predictor of Adverse Outcomes in COVID-19

Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and platelet to lymphocyte ratio to predict the severity of COVID-19

The Impact of Peripheral Eosinophil Counts and Eosinophil to Lymphocyte Ratio (ELR) in the Clinical Course of COVID-19 Patients: A Retrospective Study

Prognostic role of Interleukin-6/lymphocytes ratio in SARS-CoV2 related pneumonia

Click or tap here to enter text.In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

Specifications/Comments (e.g., if payments were made to you or to your institution) Time frame: Since the initial planning of the work 1 All support for the present manuscript (e.g., funding,x None

Specifications/Comments (e.g., if payments were made to you or to your institution)provision of study materials, medical writing, article processing charges, etc.)

Click the tab key to add additional rows. Specifications/Comments (e.g., if payments were made to you or to your institution) Please place an "X" next to the following statement to indicate your agreement:x I certify that I have answered every question and have not altered the wording of any of the questions on this form.